This article was originally published in The Tan Sheet
Federal Trade Commission consent agreements with the Arthritis Pain Care Center and Body Systems Technology are made final by 4-0 votes, the commission announces Sept. 20. Under the terms of the deals, the Arthritis Pain Care Center is not allowed to make cancer treating claims for its fatty acid product, while Body Systems Technology may not claim its shark's cartilage and cat's claw products are effective treatments for cancer, HIV/AIDS or arthritis. FTC announced the proposed agreements June 24 (1"The Tan Sheet" June 28, p. 4)
You may also be interested in...
A Federal Trade Commission consumer guide on fraudulent marketing on the Internet includes a special section on dietary supplements.
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands